Impact of 2012 USPSTF Guideline Against PSA Screening Explored

This article originally appeared here.
Share this content:
Impact of 2012 USPSTF Guideline Against PSA Screening Explored
Impact of 2012 USPSTF Guideline Against PSA Screening Explored

TUESDAY, Dec. 29, 2015 (HealthDay News) -- Patients undergoing prostate needle biopsies after the 2012 U.S. Preventive Services Task Force (USPSTF) recommendation against prostate-specific antigen-based screening for prostate cancer for men of any age are more likely to be diagnosed with high-risk disease, according to research published in the January issue of The Journal of Urology.

John S. Banerji, M.D., from the Virginia Mason Medical Center in Seattle, and colleagues reviewed data from a prospective database of patients undergoing prostate needle biopsies from 2004 to 2014. The authors compared patients seen before and after the USPSTF recommendations.

The researchers found that, compared with the 1,416 patients in the pre-USPSTF group, the 310 patients in the post-USPSTF group had a higher prostate-specific antigen (P < 0.001); they were also more likely to be diagnosed with higher clinical stage (2b, P = 0.003; 2c-3a, P = 0.027) and D'Amico high-risk prostate cancer (P = 0.036), with an adjusted relative risk of 1.25 for high-risk prostate cancer. Similar results were seen when the pre-USPSTF group was limited to 448 patients seen in the 30 months before the draft guidelines. There was a 31 percent decrease in the absolute number of biopsies performed, with most of the decrease occurring in the detection of intermediate-risk tumors.

"Future focus on informed application of screening techniques may prevent the reversal of decades of improvement in the prostate cancer mortality rate," the authors write.

Abstract
Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease


More in Home

ASTRO: No Survival Benefit for Adding EBT to Brachytherapy

ASTRO: No Survival Benefit for Adding EBT to ...

Addition of external beam therapy doesn't improve five-year progression-free survival in prostate cancer

ASTRO: Fewer Side Effects With IMRT in Cervical, Endometrial CA

ASTRO: Fewer Side Effects With IMRT in Cervical, ...

Patients in conventional radiotherapy arm had more high-level adverse events than those in IMRT arm

Many Doctors Reluctant to Reveal Mental Health Issues

Many Doctors Reluctant to Reveal Mental Health Issues

Perceived stigma, fear of career repercussions hinder treatment, study suggests

is free, fast, and customized just for you!

Already a member?

Sign In Now »